Infrequently renal carcinoma presents with skin metastases which may look benign, and are missedby unwary clinicians. We present three such cases and discuss their management. Case reports Case 1 A 77-year-old woman presented to her GP with a rapidly growing chest lesion, first noticed 6 weeks previously. She attended surgical outpatients where the superficial, 2 em, irregular, firm lesion was labelled a neurofibroma and later excised under local anaesthetic. It appeared benign and, although histology was sent, she was discharged.
Four months later, after it regrew, the histology report of 'malignant clear cells most likely of renal origin' was discovered. In the next clinic no symptoms, signs or haematuria were found, although ultrasound and CT scans revealed a localized left renal tumour.
She had a radical right nephrectomy and re-excision of the skin lesion and recovered well, histology proving identical to the original lesion ( Figures 1 and 2) . Lymph nodes and a bone scan were clear. Fifteen months later skin and breast metastases have appeared and repeat bone scan shows widespread bony involvement. She is now receiving interleukin II.
Case 2
A 44-year-old man presented to his GP with a 6 mm lump on his elbow which had grown over 6 months. It was removed and, because of a fleshy, vascular appearance, sent for histology. This revealed clear cells consistent with a renal primary and prompted a CT scan and urological referral.
On review he was a fit man with no stigmata of renal carcinoma, although scans showed a 5 em mass in the lower pole of the right kidney. This was excised by a radical nephrectomy and he remains disease free 12 months later.
Case 3
A 70-year-old man was sent to a dermatologist with a 7 mm right shoulder lump which had appeared over 2 weeks and was deep red and tethered. It was excised and labelled a secondary tumour until histology showed clear cells pathognomonic of renal carcinoma.
No clinical stigmata were subsequently found and, after discussion with a urologist, no action was taken. Two months later he represented in Accident & Emergency with a painful, swollen arm and X-rays showed pathological fracture of the humerus and multiple pulmonary metastases. He is receiving palliation with medroxyprogesterone.
Discussion
Three to 11% of renal carcinomas metastasize to skin", about 7% of all skin metastases. Up to 20% of these will be the presenting feature'", They are distributed throughout the body, commonest in the head and neck", frequently appear benign and 50% are misdiagnosed.
They may be smooth, solitary, rapidly growing intradermal lumps which often recur-(case 1) and ulcerate'' although subcutaneous infiltration-and 'sebaceous horns' 3 are reported. Suspicion is raised by rapid growth and atypical appearance. Histologically, cells characteristic of the underlying renal carcinoma" are found. Weiss" showed 75% of patients with skin involvement had lung metastases at postmortem, and Hellsten" demonstrated 82% of metastases involve multiple sites.
Twenty-five to 57% of patients with renal carcinoma have metastases at presentation and this is of prime prognostic significance", Their treatment is uncertain and prognosis poor, with survival of 26% at one year and only 4% at 3 years", The place of nephrectomy is unclear, although many justifications are offered.
Nephrectomy controls primary related symptoms, be they local (pain, haematuria, pressure) or systemic (hormonal). These are only found in 28% of patients" and medical management may obviate surgery.
Metastases are solitary in 1.6-3.6% of patients'? and excision of these with nephrectomy improves survival!', which is between 29% and 50% at 5 years l 2 • Middleton'f shows prognosis improves if the metastasis is in soft tissues and presents late.
Spontaneous remission of renal carcinoma is recognized, in which case debulking nephrectomy may promote this.
It is rare (0.3-0.8% of cases) and has occurred without previous nephrectomy'", the mortality of which is 5_6%18. Interestingly, spontaneous regression of skin metastases is reported14.
In combined treatment, both nephrectomy and available treatment modalities must be proven. Renal carcinoma is unresponsive to both chemotherapy and radiotherapy. Although medroxyprogesterone acetate palliates some cases, there are side effects and survival remains unchanged. Response to interferon is about 15% and probably depends on tumour mass, but its role is unclear'", Interleukin II is still experimental, although early results seem promising and offer hope to future patients".
Renal carcinoma rarely presents with skin metastases which mimic benign lesions and are easily misdiagnosed. Histology must always be sent on excised skin lesions. The prognosis for patients who present with skin and other metastases is poor and nephrectomy rarely indicated. Until this serendipitous tumour can be better understood and treated, the management of metastatic renal carcinoma will depend on the preferences of the individual patient and surgeon.
